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Abstract 
Huntington’s disease is an inherited neurodegenerative disorder caused by a CAG repeat 
expansion in the huntingtin gene. The peripheral innate immune system contributes to 
Huntington’s disease pathogenesis and has been targeted successfully to modulate disease 
progression, but mechanistic understanding relating this to mutant huntingtin expression in 
immune cells has been lacking. Here we demonstrate that human Huntington’s disease myeloid 
cells produce excessive inflammatory cytokines due to cell-intrinsic effects of mutant 
huntingtin expression. A direct effect of mutant huntingtin on the NFB pathway, whereby it 
interacts with IKK, leads to increased degradation of IB and subsequent nuclear translocation 
of RelA. Transcriptional alterations in intracellular immune signalling pathways are also 
observed. Using a novel method of small interfering RNA delivery to lower huntingtin 
expression, we show reversal of disease-associated alterations in cellular function - the first 
time this has been demonstrated in primary human cells. Glucan-encapsulated small interfering 
RNA particles were used to lower huntingtin levels in human Huntington’s disease 
monocytes/macrophages, resulting in a reversal of huntingtin-induced elevated cytokine 
production and transcriptional changes. These findings improve our understanding of the role 
of innate immunity in neurodegeneration, introduce glucan-encapsulated small interfering 
RNA particles as tool for studying cellular pathogenesis ex vivo in human cells and raise the 
prospect of immune cell-directed HTT-lowering as a therapeutic in Huntington’s disease. 
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Introduction 
Huntington’s disease is an incurable, autosomal dominant neurodegenerative disorder caused 
by a CAG repeat expansion in exon 1 of the huntingtin (HTT) gene leading to an expanded 
stretch of 36 or more glutamine residues in the N-terminal region of the HTT protein (The 
Huntington's Disease Collaborative Research Group, 1993). The disease is characterised by 
progressive cognitive, psychiatric and motor impairments caused by neuronal dysfunction and 
cell death. 
Whilst primary pathology in Huntington’s disease is believed to arise from basal ganglia 
degeneration, HTT expression has been found in all tissues studied (Li et al., 1993). 
Indeed, numerous studies of Huntington’s disease patients and mouse models have 
described abnormalities in peripheral tissues, including weight loss, muscle wasting, 
diabetes and changes in the neuro-endocrine system (van der Burg et al., 2009). Mutant HTT 
expression in non-neuronal cells in both the brain and the periphery may contribute 
to Huntington’s disease neuropathology.  
HTT is expressed in immune cells (Weiss et al., 2012), and both central and peripheral immune 
system abnormalities have been shown in Huntington’s disease patients (Soulet and Cicchetti, 
2011). Microglia, the resident immune cells of the brain (Ransohoff and Perry, 2009), are 
sustained by self-renewal (Ajami et al., 2007), however disrupting the blood brain barrier by 
irradiation has shown that blood monocytes are able to populate the brain (Simard and Rivest, 
2004). Microglial activation, seen in post-mortem Huntington’s disease brain tissue (Sapp et 
al., 2001) and by PET imaging, occurs in Huntington’s disease gene carriers before symptom 
onset (Tai et al., 2007). We have previously demonstrated peripheral immune system 
dysfunction in Huntington’s disease, including changes in innate immune proteins in patient 
plasma (Dalrymple et al., 2007).  Moreover, elevated plasma cytokine (Björkqvist et al., 2008) 
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and chemokine (Wild et al., 2011) levels in patients correlate with disease progression and can 
be detected years before disease onset. We have shown that primary human monocytes are 
hyper-reactive in response to lipopolysaccharide (LPS), producing increased levels of 
interleukin (IL)-6. This phenotype is replicated in murine mutant HTT expressing macrophages 
and microglia, demonstrating that peripheral cells could mirror pathology in the CNS in 
Huntington’s disease (Björkqvist et al., 2008). 
Furthermore, several recent studies have suggested that the peripheral immune system can act 
as a modifier of Huntington’s disease neuropathology. Transplantation of wild-type bone 
marrow into Huntington’s disease mice partially rescues their motor defects, increases 
synaptogenesis and reduces elevated plasma cytokine levels (Kwan et al., 2012). Peripheral 
administration of a kynurenine 3-monooxygenase (KMO) inhibitor extends lifespan, prevents 
synaptic loss and decreases microglial activation in Huntington’s disease mice. As the drug 
cannot cross the blood brain barrier, the neuroprotective effect is secondary to inhibition of 
KMO in peripheral immune cells (Zwilling et al., 2011). Furthermore, treatment with a 
cannabinoid receptor 2 (CB2) agonist known to dampen immune responses, suppresses motor 
deficits and CNS inflammation whilst extending life span in a Huntington’s disease mouse 
model. This positive effect can be blocked with an antagonist that is restricted to the periphery, 
demonstrating the importance of peripheral immune cells in modulating pathogenesis 
(Bouchard et al., 2012). These studies provide strong evidence that the immune system plays 
a disease-modifying role in Huntington’s disease neuropathogenesis, but the mechanism(s) by 
which mutant HTT expression in immune cells causes this dysfunction has not yet been 
established.  
Intracellular signalling pathways leading to the activation of the transcription factor NFB are 
important regulators of cytokine production and play a key role in inflammation. Events such 
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as the activation of Toll-like receptors (TLRs) lead to signal transduction via adapter proteins 
MyD88 and IRAK1, leading to the phosphorylation and activation of IKK. This kinase 
phosphorylates IB, which is then ubiquitinated and degraded by the proteasome, whereby it 
dissociates from the NFB transcription factor subunits (RelA, RelB, cRel, NFB1, NFB2) 
that it sequesters in an inactive state in the cytoplasm. The free NFB molecules can then 
translocate into the nucleus and activate gene transcription (Hayden and Ghosh, 2012). The 
NFB pathway has previously been implicated in Huntington’s disease, with Khoshnan et al. 
having shown in inducible PC12 cells and striatal extracts from R6/2 Huntington’s disease 
mice that overexpression of mutant HTT exon 1 can activate the NFB pathway by directly 
interacting with IKK (Khoshnan et al., 2004). Similarly, a recent study has shown enhanced 
NFB signalling in astrocytes isolated from R6/2 mice (Hsiao et al., 2013). It remains to be 
shown that this interaction also occurs in a human system with expression of full-length HTT 
at normal allelic expression levels. 
The present work seeks to identify the mechanism of dysfunction in primary human 
Huntington’s disease monocytes and macrophages ex vivo. We have characterised immune cell 
dysfunction by detailed cytokine profiling and study of upstream intracellular signalling 
pathways, identifying NFB pathway dysregulation as the cause of immune dysfunction. We 
have used overexpression studies and a novel small interfering RNA (siRNA)-mediated knock-
down technique to investigate the role cell-intrinsic HTT plays in human Huntington’s disease 
monocyte and macrophage function, demonstrating the feasibility of reversing peripheral 
immune dysregulation by cell-targeted HTT-lowering.  
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Materials and methods 
Collection and classification of human samples  
All human experiments were performed in accordance with the Declaration of Helsinki and 
approved by University College London (UCL)/UCL Hospitals Joint Research Ethics 
Committee. All subjects provided informed written consent. Classification of patients is 
detailed in the Supplementary experimental procedures. Subjects’ demographic are provided 
in Table S1. 
Isolation of human monocytes and macrophages 
Cells were isolated from whole blood, as previously described (Björkqvist et al., 2008) and in 
Supplementary experimental procedures. Cells were cultured in RPMI culture medium 
supplemented with 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin and 50 g/ml 
streptomycin (Invitrogen).  Monocytes were allowed to rest for 16 h before experimental use. 
Culture medium was supplemented with 20 ng/ml GM-CSF for 6 days to differentiate 
monocytes into macrophages. 
Mutant HTT expression in U937 cells 
U937 cells (Sundström and Nilsson, 1976) were transduced with lentiviral constructs 
containing human HTT exon 1 sequences with either 29, 71 or 129 CAG repeats, together with 
GFP, or a control vector containing GFP but no HTT exon 1. For details of vectors, viral 
production and transduction, see Supplementary experimental procedures. Transduced U937 
cells were tested for HTT protein expression using a time resolved fluorescence resonance 
energy transfer (TR-FRET) immunoassay. HTT exon 1 expressing U937 cells were seeded into 
24-well plates at 5x 105 cells per well and differentiated into mature monocytes using 10 nM 
phorbol 12-myristate 13-acetate (PMA) for 3 days  (Alciato et al., 2010) before cytokine 
profiling.  
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HTT silencing 
Monocytes and macrophages were incubated with 1,3-D-glucan-encapsulated siRNA 
particles (GeRPs) for 4 hours, after which fresh medium was added to the cultures. GeRP 
uptake was visualised by seeding 1x105 monocytes per 13 mm coverslip, incubating them with 
empty green fluorescent GeRPs for 12 h and mounting onto slides with 1 g/ml DAPI. Images 
were acquired using a Zeiss 510 meta microscope (Objective 63x/1.4 Oil DIC, 1024x1024), 
overlaying the bright-field image of the cells with the 405 nm and 488 nm fluorescence 
channels for DAPI and green fluorescence, respectively. Macrophages, which were transfected 
on day three of the differentiation protocol, were transfected with green fluorescent GeRPs 
containing no siRNA at various ratios (1-1; 1-3; 1-10) before uptake rates were measured by 
flow cytometry. Cells were fixed with 3.7% paraformaldehyde for 10 min, washed with FACS 
buffer (PBS containing 1% FCS and 0.02% sodium azide) and resuspended in 200 μl FACS 
buffer for analysis by flow cytometry (FACSCalibur with CellQuest Pro BD Bioscience). Data 
analysis was performed using FlowJo 7.2.5 (Tree Star). To examine the effects of  
knockdown on cytokine production, macrophages were treated with either scrambled or anti-
HTT siRNA containing GeRPs at a 1:10 cell: particle ratio on day 3 of the differentiation 
protocol; stimulation of the cells took place three days later. To examine the effects of  
knockdown on transcriptional dysregulation, monocytes were treated with either scrambled or 
anti-HTT siRNA containing GeRPs at a 1:10 cell: particle ratio, before qPCR analysis three 
days later.  
Cytokine profiling  
All cells were seeded at 5x105 cells per well in 24-well plates and isolated/ differentiated/ 
transduced as described above. For stimulation, medium was changed to fresh cell culture 
medium containing 10 ng/ml IFN (R & D Systems) and 2 μg/ml LPS (Sigma-Aldrich, E.coli 
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055:B5, strain 1644-70. Cat. number L6529). After 24 h, supernatants were harvested and 
analysed using MSD multiplex assays, according to manufacturer’s instructions (MesoScale 
Discovery). For monocytes the pro-inflammatory (7-plex) assay was used, however IFN 
measures were not analysed as we used IFN as stimulus. For all other cell types, the pro-
inflammatory II (4-plex) assay was used and all data is shown. Monocyte data was adjusted to 
basal cytokine levels, whilst all other cell types were normalised to total protein concentration 
in each well. Cells were lysed in 50 mM Tris pH 8, 150 mM NaCl, 0.5% sodium deoxycholate, 
0.5% Triton X-100 and assayed for total protein concentration using a Bradford-based protein 
assay (Bio-Rad). 
TR-FRET quantification of HTT 
TR-FRET immunoassay quantification of total HTT and soluble mutant HTT was performed 
as previously described (Baldo et al., 2012) and is detailed in the Supplementary experimental 
procedures. 
PCR arrays 
SABioscience Human NFB Signaling Pathway RT²Profiler™ PCR Arrays were used in 
combination with the QIAGEN RNeasy Mini Kit for RNA isolation from 2x106 cells.  RNA 
integrity was evaluated using 2100 RNA Bioanalyser chips (Agilent). RNA was reverse 
transcribed using the RT2 First Strand kit for cDNA transcription, before the RT2 SYBR Green 
qPCR Mastermix and pre-primer coated PCR plates were used for qPCR (SABioscience). All 
kits were used according to manufacturer’s instruction.  
For standard SYBR Green protocols and bioinformatics used for Figure S6, see Supplementary 
experimental procedures. 
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Proximity ligation assays 
Proximity ligation assays (PLA) were conducted on monocyte-derived macrophages seeded on 
13 mm coverslips. Cells were fixed in 4% PFA for 10 min and permeabilised with 100% ice 
cold methanol at -20°C for 15 min. Coverslips were blocked with 10% BSA for 30 min at 37°C 
before staining with primary antibodies was performed for 1 h at 37°C (mouse anti-HTT 4C9, 
1:300, kind gift from Novartis; rabbit anti-IKK 1:100, Santa Cruz; rabbit anti-IKK 1:25, 
Santa Cruz). Instead of using fluorescently labelled secondary antibodies, a proximity ligation 
approach was applied following manufacturer’s instructions (Sigma). Briefly, samples were 
incubated with secondary antibodies conjugated with DNA probes (minus anti-mouse and plus 
anti-rabbit DNA probes). Probes were hybridised and ligated, followed by amplification of the 
DNA template in a rolling circle amplification reaction. Detection solution was added to 
identify amplified DNA. Signals were detected using a Zeiss LSM 710 confocal microscope 
(Objective plan-apachromat 40x/1.4 Oil DIC M27, 1024x1024). Spots were quantified using 
Volocity (PerkinElmer) on at least seven fields of view per subject, taken of random sides of 
each coverslips.  
Immunoblot analysis of IB degradation 
Monocytes were seeded at 1x106 cells/well into 24-well plates and rested for 16 h. Cells were 
stimulated with 2 g/ml LPS over a 2 h or 24 h time-course before extraction of lysates for 
western blotting (see Supplementary experimental procedures for detail). 
NFB RelA translocation 
CD14+ monocytes were seeded at 2x106 into 6-well plates and left to rest for 16 h. The cells 
were stimulated with 2 g/ml LPS before being scraped off the plates. Pelleted cells were fixed 
for 15 min and permeabilised for 10 min using the eBioscience Fix/Perm solutions, before 
NFB p65/RelA XP antibody (1:200; Cell Signaling) diluted in permeabilisation buffer was 
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added. After 30 min incubation shaking at 4°C, cells were washed twice with FACS buffer and 
spun 5 min at 300 xg. Secondary anti-rabbit IgG PE (eBioscience) was added at 1:100 in FACS 
buffer and incubated for 30 min before washing the cells twice with FACS buffer. Cells were 
resuspended in 80l FACS buffer and stained with 1 g/ml DAPI just before analysis. Samples 
were run on the ImageStreamX (Amnis) and analysed using the IDEAS software. Briefly, 
gating on single cells, the similarity feature (Similarity_Erode(Object (M04,BF,Tight)2)_Dapi 
_RelA) was used to establish the rate of RelA translocation by measuring the overlap of DAPI 
and RelA staining. Translocation rate was normalised to baseline levels for each subject.  
Statistical analysis  
For cytokine profiling data, inter-group differences were identified by one-way ANOVA with 
post-hoc Tukey HSD testing to allow for multiple comparisons. Data were corrected for age 
and gender before analysis. Linear regression with log10 transformed data was used to establish 
whether cytokine production by primary human monocytes and macrophages correlate with 
CAG repeat length. Cytokine profiling data from U937 cells and knock-down cells were 
analysed by two-way ANOVA with Bonferroni post-tests. Gene expression changes measured 
by qPCR were analysed using unpaired two-tailed student t tests. Paired two-tailed student t 
tests were used to analyse the effects of anti-HTT siRNA compare to scrambled siRNA in cells 
from the same individual. All error bars represent standard error of the mean.  
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Results 
Huntington’s disease patient monocytes and macrophages are hyper-reactive after 
LPS stimulation 
Previously we have shown that Huntington’s disease patient monocytes produce increased 
levels of IL-6 upon stimulation with LPS (Björkqvist et al., 2008). To extend these findings to 
other cytokines, we collected blood samples from a large cohort (n=53) of HTT gene carriers 
ranging from pre-manifest to moderate disease-stages and control subjects (n=27) (Table S1). 
CD14+ monocytes were isolated, primed with IFN and stimulated with LPS ex vivo. 
Monocytes from Huntington’s disease gene carriers at each disease-stage were found to 
produce more IL-6 and TNFthan control cells (Figure 1A). Furthermore, IL-1 production 
by pre-manifest monocytes was significantly increased. IL-8, IL-10 and IL-12 levels did not 
differ between Huntington’s disease and control cells (Figure 1A).   
When monocytes migrate into tissues, they differentiate into macrophages capable of eliciting 
effective immune responses to localised inflammatory signals (Gordon and Taylor, 2005). To 
test whether Huntington’s disease macrophages are abnormal too, blood monocytes were 
differentiated into macrophages using GM-CSF and stimulated with IFN and LPS to assess 
their cytokine profile. In keeping with our previous findings, macrophages from all 
Huntington’s disease stages produced significantly higher levels of TNF than control cells 
(Figure 1B).  Furthermore, IL-8 levels were also significantly increased in Huntington’s disease 
macrophages (Figure 1B). This marks a shift in the pro-inflammatory cytokines elevated, when 
comparing to the pattern seen in monocytes (Figure 1A), where IL-8 was not changed. This is 
likely due to the distinct functions of the two cell types. 
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These data show that myeloid cells isolated from Huntington’s disease patients are hyper-
reactive, producing elevated levels of several key pro-inflammatory cytokines following 
stimulation. 
Correlating production of individual cytokines to CAG repeat length showed a significant 
association (p=0.048) of CAG repeat length with TNF produced by Huntington’s disease 
monocytes (Figure S1). There was no correlation between CAG repeat length and levels of any 
other cytokine in either Huntington’s disease monocytes or macrophages. 
Lowering HTT levels reverses Huntington’s disease myeloid cell hyper-reactivity 
Lowering HTT expression using siRNA is a promising therapeutic approach for Huntington’s 
disease (Sah and Aronin, 2011). Therefore, we investigated whether lowering total HTT levels 
can reverse the hyper-reactive phenotype in primary Huntington’s disease monocytes and 
macrophages. Using a novel approach that takes advantage of these cells’ ability to 
phagocytose (Aouadi et al., 2009), 1,3-D-glucan-encapsulated siRNA particles (GeRPs) were 
packaged with, previously validated (DiFiglia et al., 2007), anti-HTT siRNA for delivery into 
human ex vivo monocytes or monocyte-derived macrophages. Monocytes cultured with the 
GeRPs readily ingested them via phagocytosis (Figure 2A), without effect on cell viability 
(Figure S2). Testing different macrophage-to-GeRP ratios, up to 90% of macrophages 
phagocytosed the green fluorescent GeRPs when they were added at a ten-fold particle to cell 
ratio, demonstrating high transfection efficiency at this concentration (Figure 2B).  
The efficacy of the anti-HTT siRNA GeRPs was tested three days after siRNA delivery in 
macrophages, using both qPCR for HTT RNA levels and TR-FRET immunoassay for HTT 
protein levels. Macrophages treated with anti-HTT siRNA GeRPs had 60-70% less HTT mRNA 
and 50% less HTT protein, compared to macrophages treated with scrambled siRNA-
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containing GeRPs (Figure 2C). As expected, the decrease in HTT levels was the same in both 
control and disease macrophages (Figure 2C).  
Next, we examined the effect of lowering total HTT levels on cytokine production. After 
treating primary human monocyte-derived macrophages with anti-HTT or scrambled siRNA 
GeRPs for three days, IFN-primed macrophages were stimulated with LPS and cytokine 
production was measured. Validating our previous findings, IL-8 and TNF levels were 
significantly higher in Huntington’s disease than in control cells, when both had been treated 
with scrambled siRNA (Figure 3). However, lowering HTT levels in Huntington’s disease 
macrophages using anti-HTT GeRPs rescued this increase by significantly decreasing the 
production of IL-6, IL-8 and TNF (Figure 3). IL-1 production showed a similar trend that 
did not reach significance. Interestingly, lowering HTT levels also significantly reduced IL-6, 
IL-8 and TNF levels in control cells, suggesting a role of wild-type HTT in cytokine 
production. 
Thus, lowering HTT levels by 50% using this novel method of siRNA delivery can reverse the 
hyper-reactivity of Huntington’s disease patient macrophages. The use of GeRPs to achieve 
cell-targeted gene knockdown has to date shown significant promise in mice, but this is the 
first report showing efficient siRNA delivery, pathogenic gene knock-down and rescue of a 
deleterious phenotype using this method in primary human immune cells. 
The use of HTT-lowering in Huntington’s disease patient myeloid cells demonstrates that their 
production of cytokines in response to stimuli is regulated by HTT. This suggests that immune 
cell dysfunction is caused by the cell-intrinsic expression of mutant HTT, rather than being 
secondary to extracellular disease-associated factors. To confirm this, we transduced 
histiocytic lymphoma U937 cells, a commonly-used model of monocytes (Alciato et al., 2010), 
with lentiviral vectors expressing human HTT exon 1. The constructs contained either wild-
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type HTT exon 1 with 29 CAG repeats, or mutant HTT exon 1 with 71 or 129 CAG repeats. 
Sorting the transduced cells using the co-expressed GFP resulted in 99% pure cultures (Figure 
S3) and HTT expression in the transduced cells was confirmed using TR-FRET (Figure 4A). 
The HTT exon 1-expressing U937 cell lines were differentiated with PMA for 3 days to induce 
a mature monocyte phenotype before stimulating the cells with IFN and LPS, and analysing 
their cytokine profile. Stimulated U937 cells expressing either 71 or 129Q mutant HTT exon 1 
produced significantly increased levels of IL-6 and TNF compared to those expressing the 
29Q wild-type HTT exon 1 construct (Figure 4B). Cells expressing 129Q produced 
significantly higher IL-1 levels compared to control, whereas IL-8 levels did not differ.  
Taken together, modulating HTT levels via overexpression of mutant HTT exon 1 in a myeloid 
cell line and by knock-down of HTT in primary human peripheral immune cells demonstrates 
that cell-intrinsic expression of mutant HTT causes the hyper-reactive immune phenotype 
observed in monocytes and macrophages from Huntington’s disease patients.  
Mutant HTT interacts with the NFB pathway in human Huntington’s disease 
myeloid cells 
That Huntington’s disease patient monocytes and macrophages resemble normal cells when 
unstimulated, but are hyper-reactive in response to LPS, suggests that mutant HTT affects the 
signalling cascade induced by LPS. Expression of the main LPS receptor, TLR4, was unaltered 
(Figure S4), suggesting downstream effects. The NFB pathway, a key signalling cascade 
downstream of TLR4, has previously been shown to interact with mutant HTT exon 1 in mice 
(Khoshnan et al., 2004). 
To test whether this interaction occurs in human primary immune cells, peripheral blood 
mononuclear cells (PBMCs) from early-stage Huntington’s disease patients and control 
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subjects were isolated for co-immunoprecipitation experiments. Full-length HTT was 
detectable in both the control and Huntington’s disease samples with two anti-HTT antibodies 
(2B7 and MAB2166), whereas co-precipitation of IKK was observed only in the Huntington’s 
disease sample (Figure S5A). Given the high background signal in these experiments due to 
poor antibody performance in the immunoprecipitation, we performed more sensitive 
proximity ligation assays to detect native IKK-HTT interactions in the cells. As shown in 
Figure 5A, specific IKK-HTT protein interactions, represented by red spots can be detected 
in both control and disease macrophages. Quantification of the number of spots per cell 
demonstrated more interaction between IKK and HTT in Huntington’s disease patient cells 
compared to controls (Figure 5B). Further evidence for a CAG repeat dependent interaction 
between HTT and the IKKcomplex was given by an increased number of interactions between 
HTT and the IKKsubunits in Huntington’s disease samples (Figure 5B). The fact that 
classical immunoprecipitation did not pick up an interaction of the proteins in control 
individual’s cells is likely to be due to the method being less sensitive. These data demonstrate 
for the first time a direct interaction between the IKKcomplex and full-lengthHTT expressed 
at normal allelic expression levels in primary human cells.  
Activation of the IKK complex leads to the phosphorylation and degradation of IB, the 
endogenous inhibitor of NFB (Hayden and Ghosh, 2012). To evaluate whether the increased 
interaction of mutant HTT with IKK leads to increased IKK complex activation and 
subsequent changes in IB degradation, we stimulated Huntington’s disease and control 
monocytes with LPS over a time-course of two hours to analyse IB levels by western blot. 
Control monocytes demonstrated a drop in IB levels over the first 15 minutes, followed by a 
recovery of IB levels over the next two hours, representing a normal pattern of NFB 
activation upon stimulation (Figure 5C) (Gross and Piwnica-Worms, 2005). Following 
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stimulation of Huntington’s disease monocytes, we observed a different pattern: IB levels 
dropped within 5 minutes and did not recover to baseline levels within the two hour time-course 
(Figure 5C). This demonstrates that IB is degraded more rapidly and over a prolonged period 
of time in primary human Huntington’s disease monocytes due to IKK activation. Similarly, 
levels of phosphorylated IB were increased over the two hour period in monocytes isolated 
from Huntington’s disease patients compared to controls (Figure S5B).  To investigate by 
which time IB levels return to baseline in Huntington’s disease patients, we performed a 
prolonged time-course over 24 h and found that IB levels returned to baseline levels or above 
(due to high level re-synthesis of the protein) by 4 h post-stimulation (Figure S5C). These 
findings demonstrate a transient effect of mHTT expression on IB levels following 
stimulation. 
Under steady-state conditions, IB binds NFB and blocks its translocation to the nucleus. 
Degradation of IB allows the NFB transcription factors to enter the nucleus and influence 
transcription (Beinke and Ley, 2004). In order to test whether increased IB degradation in 
Huntington’s disease monocytes leads to more rapid nuclear translocation of NFB, we 
analysed translocation of RelA, one of five DNA-binding NFB subunits, in Huntington’s 
disease and control monocytes using imaging flow cytometry. ImageStream technology, 
combining the high image content information of microscopy with the high throughput analysis 
of flow cytometry, is used to overcome the limitations of conventional assays to produce highly 
reproducible and statistically robust data (Maguire et al., 2011). Cells were stained with DAPI 
to mark the nucleus and with anti-RelA antibodies (Figure 5D). Analysis of the levels of RelA 
and DAPI co-localisation showed significantly higher levels of RelA translocation in 
Huntington’s disease than in control monocytes at 45 and 90 minute post LPS stimulation 
(Figure 5E). 
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Thus, we demonstrate in primary Huntington’s disease patient cells that mutant HTT binds 
IKK and causes increased NFB activity by increased IB degradation and subsequent NFB 
translocation. We hypothesise that this causes altered transcription of NFB target genes, 
leading to increased cytokine production by immune cells. 
Transcriptional changes affect signalling pathways in Huntington’s disease 
myeloid cells  
Transcriptional dysregulation is a central pathogenic mechanism in Huntington’s disease 
(Hodges et al., 2006). Therefore, we tested whether basal differences in transcription play a 
role in mutant HTT induced immune hyper-reactivity by analysing differences in the 
expression of genes related to the NFB pathway. The mRNA expression of 84 genes was 
tested in untreated human monocytes using the SABioscience NFB signalling pathway PCR 
array. We identified seven genes that were significantly up-regulated (TLR2, LTBR, CD40, 
TMED4, AKT1, IL10, FR2) and one gene that was significantly down-regulated (CHUK) in 
Huntington’s disease compared to control monocytes (Table 1). Four of the up-regulated genes 
showed a ≥1.5-fold change: CD40 (1.5); AKT1 (1.5); IL10 (1.85) and F2R (2.23). Furthermore, 
the adaptor molecules IRAK1, TICAM2, MYD88, and TRADD, were also up-regulated (Table 
1 and Figure S6). Interestingly, CHUK, which encodes for IKK, was found to be down-
regulated, whilst all other parts of the IKK complex, IB and the NFB transcription factors 
were unchanged. 
The array also screened intracellular signalling pathways closely linked to the NFB pathway, 
such as MAPK and PI3K/AKT pathways. Increased AKT protein levels have been found in 
Huntington’s disease patient lymphoblasts (Colin et al., 2005) and AKT1 is one of the genes 
up-regulated in Huntington’s disease monocytes (FC=1.5, p=0.031). Moreover, the genes 
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composing the transcription factor AP-1, JUN and FOS, are also up-regulated in Huntington’s 
disease monocytes (Table 1 and Figure S6). Therefore, both of these pathways may also 
contribute to the increased immune response observed after stimulation of Huntington’s disease 
monocytes.  
To validate our findings, six candidate genes chosen on the basis of array fold changes and 
their importance within the NFB signalling cascade (CD40, AKT1, IRAK1, JUN, IL6 and 
IL10) were quantified by qPCR using different primer sets and cells from a different patient 
cohort. The relative changes in gene expression when comparing Huntington’s disease and 
control human monocytes matched our previous findings for all six genes (Figure S7). 
Expression levels for CD40, IRAK1 and IL10 were significantly increased in Huntington’s 
disease compared to control monocytes, whilst expression changes in AKT1, JUN and IL6 
demonstrated an upwards trend, not reaching statistical significance due large inter-individual 
differences.   
Lowering HTT levels reverses transcriptional changes in Huntington’s disease 
myeloid cells 
Finally, we investigated whether lowering HTT using anti-HTT siRNA GeRPs could reverse 
the transcriptional changes observed in Huntington’s disease monocytes. IRAK1 (the main 
adapter molecule between TLR4 and NFB), CD40 (immunomodulatory molecule giving co-
stimulatory signals to both innate and adaptive immune cells) and JUN (part of the AP-1 
transcription factor) expression were all increased in Huntington’s disease monocytes (Table 
1).  Following three days of treatment with GeRPs containing either scrambled or anti-HTT 
siRNA, we analysed the expression of these candidate genes by qPCR. HTT mRNA levels 
were assessed to validate the knock-down. Treatment with anti-HTT siRNA resulted in a 50% 
reduction in HTT levels in both Huntington’s disease and control monocytes (Figure 6A/B). 
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However, only the Huntington’s disease monocytes demonstrated a significant 20-30% 
reduction in IRAK1, CD40 and JUN expression when treated with anti-HTT siRNA (Figure 
6A). Lowering HTT in control cells did not affect levels of IRAK1, CD40 and JUN transcript 
expression (Figure 6B), suggesting that the transcriptional dysregulation of these genes in 
Huntington’s disease myeloid cells is caused specifically by a gain of mutant HTT function, 
rather than loss of wild-type protein function. 
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Discussion 
Plasma pro-inflammatory cytokine levels are elevated in Huntington’s disease patients, even 
in the pre-manifest stages of the disease (Björkqvist et al., 2008). Here we demonstrate that 
Huntington’s disease PBMCs are the likely source of the increased pro-inflammatory 
cytokines, as both monocytes and macrophages isolated from Huntington’s disease patients 
and stimulated with LPS produce significantly more IL-6, IL-8 and TNF compared to 
controls. Supporting our previous finding that plasma cytokine levels are already elevated in 
pre-manifest subjects with a mean of 16 years to clinical onset (Björkqvist et al., 2008), 
myeloid cells isolated from pre-manifest Huntington’s disease patients were hyper-reactive to 
the same degree as cells isolated from late-stage disease patients. Cytokine production seems 
CAG length independent and suggests an early deficit that is already present many years before 
disease onset, which may be a marker of when to intervene with potential modulatory therapies. 
Modulating HTT expression by overexpression of mutant HTT exon 1 in a monocyte-like cell 
line and lowering HTT levels in primary human monocytes/macrophages demonstrated that 
this hyper-reactive phenotype is due to a cell-intrinsic effect of mutant HTT expression and not 
non-cell autonomous secondary factors. 
Importantly, we have been able to show that lowering total HTT levels partially rescues this 
hyper-reactive phenotype, with a reversal of both elevated cytokine production and 
transcriptional changes observed in human Huntington’s disease myeloid cells ex vivo. This is 
the first report showing that lowering HTT in cells freshly isolated from Huntington’s disease 
patients can reverse cellular dysfunction caused by mutant HTT expression – an important first 
demonstration of the reversibility of cellular dysfunction after HTT-lowering in human tissue. 
HTT-lowering was achieved using a novel phagocytosis dependent approach, in which siRNAs 
are packaged into glucan particles isolated from yeast (Aouadi et al., 2009). This study is the 
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first to use this technique in primary human macrophages and demonstrates that a 90% 
transfection rate can be achieved, much higher than the 10-20% transfection rate achieved by 
traditional methods such as lentiviral transduction.  
Our findings, that lowering total HTT levels by only 50% in primary human Huntington’s 
disease macrophages and monocytes can reverse the increased cytokine production and 
transcriptional changes, respectively, validate the potential of HTT-lowering therapy as well 
as the possibility of using peripheral cells to test siRNA efficiency, safety and efficacy.  
Interestingly, cytokine release was also decreased in control macrophages treated with anti-
HTT siRNA, indicating either that HTT regulates cytokine production in a CAG dependent 
manner or that wild-type HTT influences cytokine production in parallel to mutant HTT. Wild-
type HTT has been shown to play a role in both actin remodelling (Munsie et al., 2011, Kwan 
et al., 2012) and microtubule-mediated transport (Gauthier et al., 2004). As both processes are 
needed for the trafficking of cytokines to the cell surface membrane for release (Lacy and Stow, 
2011), a reduction of wild-type HTT levels might exert a loss of function by hindering normal 
actin and microtubule remodelling causing changes in cytokine release. A future study using 
allele-specific silencing of mutant but not wild-type HTT will help determine the exact 
contributions loss of wild-type HTT and gain of mutant HTT function have on the myeloid cell 
dysfunction in Huntington’s disease.   
The NFB pathway has been previously implicated in Huntington’s disease in murine studies 
(Khoshnan et al., 2004, Thompson et al., 2009, Steffan, 2010, Hsiao et al., 2013). Investigating 
this pathway, we found that HTT binds the IKK complex in a CAG repeat length dependent 
manner. Testing HTT binding to both IKK and IKKsubunits, we detected a stronger 
interaction between HTT and IKK, suggesting this subunit as the direct interaction partner. 
IKK is the regulatory subunit of the IKK trimer, consisting of one regulatory () and two 
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kinase subunits ( and ), and is a critical component without which cells are unresponsive to 
all upstream stimuli (Israël, 2000). During signal transduction, polyubiquitin chains form the 
scaffold on which TAK1/TAB2/3 and IKK complexes are formed to induce TAK1 
dependent activation of IKKβ (Miyamoto, 2011).  In agreement with previously described 
findings using non-primary human cell model systems (Khoshnan and Patterson, 2011), we 
have shown in primary human cells that HTT can function as an alternative scaffold for the 
NFB pathway. The CAG repeat dependent binding of HTT to IKK is associated with 
increased IKK complex formation and downstream signal transduction following LPS 
stimulation in Huntington’s disease myeloid cells (Figure 7). Previously, this interaction has 
only been observed in cultured tumour cells (Khoshnan et al., 2004) or mouse models 
expressing exon 1 mutant HTT (Khoshnan et al., 2004, Hsiao et al., 2013). Here we 
demonstrate that the interaction also takes place in primary human ex vivo cells expressing the 
full-length protein at normal allelic expression levels. That mutant HTT exon 1 fragments have 
previously been shown to bind IKK is consistent however with our finding that an N-terminal 
human exon 1 mutant HTT fragment can induce elevated cytokine production in a histiocytic 
cell line and our recent report demonstrating increasing N-terminal fragmentation of mutant 
HTT in human myeloid cells as the disease progresses (Weiss et al., 2012).  
Interestingly, a recent study showed that activating the immune modulator CB2, which is 
thought to dampen NFB signalling (Rajesh et al., 2007), reduces increased serum IL-6 levels 
while extending life span and reducing motor deficits in Huntington’s disease mouse models 
(Bouchard et al., 2012). Our finding that mutant HTT alters the NFB pathway in human 
Huntington’s disease monocytes is likely to be relevant to other cell types and tissues, including 
those of the CNS. We previously showed that hyper-reactivity of Huntington’s disease 
peripheral myeloid cells is mirrored in microglia (Björkqvist et al., 2008). The NFB pathway 
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is present and active in both neurons and glial cells (O'Neill and Kaltschmidt, 1997). 
Pharmacological inhibition of NFB impairs memory and learning (Mattson and Meffert, 
2006) and NFB pathway activation is critical for neuronal survival and neurite outgrowth 
(Teng and Tang, 2010). Increased levels of NFB activity have been shown in both 
Alzheimer’s disease (AD) (Kaltschmidt et al., 1997) and Parkinson’s disease (Hunot et al., 
1997). Blocking NFB function in mutant HTT exon 1 expressing PC12 cells leads to reduced 
mutant HTT toxicity, implying that the NFB pathway contributes to neurotoxicity in 
Huntington’s disease (Khoshnan et al., 2004). Indeed, a recent study showing that mutant HTT 
enhances NFB-mediated inflammation in astrocytes to cause toxicity in the brain of 
Huntington’s disease mice underlines the potential importance of NFB in non-neuronal cells 
during neurodegeneration (Hsiao et al., 2013).   
Given the manifold roles NFB signalling plays in the different cell types, inhibiting the 
pathway to lower hyper-reactive immune function in Huntington’s disease may also affect 
other cell types. For example, compounds that target NFB activity need to be closely 
evaluated as to whether they cross the blood brain barrier and with regard to negative effects 
on synaptic activity and plasticity. However, drugs that target this pathway will not necessarily 
have negative effects. Laqinimod for example, a immunomodulatory compound inhibiting 
NFB activity (Brück et al., 2012) was well tolerated and showed decreased progression rates 
in multiple sclerosis patients in clinical trials (Comi et al., 2012). Furthermore, targeting the 
NFB pathway further downstream, for example at the level of cytokine secretion is also a 
possible therapeutic target. In a Huntington’s disease mouse model, peripherally administrated 
anti-IL-6 antibody treatment has shown improvement of disease progression (Bouchard et al., 
2012), while perispinal administration of a TNF inhibitor improves disease in Alzheimer’s 
disease patients (Tobinick et al., 2006), clearly demonstrating the positive effect of 
immunomodulatory therapy for neurodegeneration. 
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We have identified gene expression changes in key molecules involved in immune signalling 
in Huntington’s disease patients’ monocytes. Several adapter proteins downstream of TLR4, 
such as IRAK1, TICAM2 and MyD88 were found to be slightly elevated in native Huntington’s 
disease patients’ monocytes. A cumulative baseline increase in expression of several of these 
adapter proteins may lead to increased signal transduction from TLR4 to NFB, further 
increasing NFB pathway dysregulation. Another gene found to be up-regulated in 
Huntington’s disease monocytes was CD40 which, together with its ligand CD154, mainly 
expressed on T cells, regulates the immune response on several levels. Monocytes are activated 
leading to up-regulated cytokine production and antigen presentation, and priming of the 
adaptive immune system (Grewal and Flavell, 1998). This points to further functional 
abnormalities in the immune system of Huntington’s disease patients, suggesting a possible 
deficit in the communication between antigen presenting cells and the adaptive immune 
system. Furthermore, CD40 mediates cell adhesion needed for leukocyte trafficking (Alderson 
et al., 1993). Given recent studies showing defective migration in Huntington’s disease due to 
defective actin remodelling (Kwan et al., 2012), the increase in CD40 expression could be a 
compensatory response of immune cells to counteract their decreased migrative ability. FOS 
and JUN, subunits of the AP-1 transcription factor, were also upregulated in primary human 
myeloid Huntington’s disease cells. Interestingly, FOS and JUN levels have been found to be 
increased in AD patient brains (Anderson et al., 1994), and the MAP kinase needed for JUN 
activation, JNK, is elevated and involved in neurotoxicity in Huntington’s disease mouse (Fan 
et al., 2012) and rat models (Perrin et al., 2009). Thus, we cannot exclude that dysregulation 
in these signalling pathways may also contribute to the Huntington’s disease immune 
phenotype.  
In addition to the pathways identified in this study, we cannot exclude other previously 
described mechanisms, which may contribute to the transcriptional dysregulation we found in 
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primary human Huntington’s disease myeloid cells. For example, mutant HTT is known to 
bind and thereby deplete transcription factors such as CBP and p53 from their normal location 
causing changes in the genes they control (Steffan et al., 2000, Nucifora et al., 2001). 
Furthermore, HTT may alter DNA conformation upon direct binding, affecting transcription 
factors binding to their promoter regions (Benn et al., 2008). 
This study demonstrates that the cellular dysregulation observed in hyper-reactive immune 
cells in Huntington’s disease can be reversed by HTT-lowering and represents the first 
demonstration of phenotypic reversibility on HTT-lowering in primary human cells in 
Huntington’s disease. It also identifies the underlying intracellular mechanisms of immune 
dysfunction in human cells in Huntington’s disease. This is important as the immune system 
has been shown to be a powerful modifier of Huntington’s disease pathogenesis in various 
mouse models (Zwilling et al., 2011, Bouchard et al., 2012, Kwan et al., 2012). There is 
currently a search for genetic and environmental modifiers of Huntington’s disease as the CAG 
repeat expansion only explains 50-70% of variance in age of onset, and its role in modulating 
disease progression is variable (Andrew et al., 1993, Brinkman et al., 1997). The remainder of 
the variance is likely due to environmental and other genetic factors (Wexler et al., 2004). The 
immune system may be a powerful modifier of Huntington’s disease age of onset and 
progression, with an interaction of both genetic and environmental factors. This has already 
been shown to be the case in large GWAS in AD where several key genes involved in the 
innate immune system were shown to increase susceptibility to developing AD (Harold et al., 
2009, Lambert et al., 2009, Guerreiro et al., 2013). 
Our novel method of siRNA delivery has potential therapeutic relevance to Huntington’s 
disease and other diseases where immune dysregulation is a feature. Glucan particles are a 
versatile phagocytic cell targeted delivery system and have been administered by oral, 
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subcutaneous, intraperitoneal and intravenous routes in mice and rats.  In our future studies, 
we plan to administer GeRPs loaded with anti-HTT siRNA to reverse the inflammatory 
phenotype via intrathecal administration to directly target phagocytic microglial cells and 
infiltrating monocyte/macrophages, and via intravenous administration to target circulating 
monocytes and PMNs, a precursor pool for inflammatory cells trafficking into inflamed brain 
sites. 
Finally, our work also suggests a potential new therapeutic target for Huntington’s disease 
through modulating NFB activation and downstream targets. The muscle wasting, weight loss 
and depression that occurs in Huntington’s disease (van der Burg et al., 2009) may be related 
to increased peripheral cytokine levels. Therefore, modulating the immune system may have 
beneficial effects in both the CNS and the periphery. Indeed, a peripherally administered anti-
inflammatory, anti-IL-6 antibody treatment in R6/2 mice has already been show to improve 
both weight loss and disease progression (Bouchard et al., 2012). This work therefore has 
implications for both understanding the role of the innate immune system as a modifier of 
neurodegeneration and modulation of the immune system as a possible therapeutic in 
Huntington’s disease. 
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Figure 1: Pro-inflammatory cytokine production by monocytes and macrophages is 
elevated in Huntington’s disease patients. Innate immune regulators such as IL-6, IL-8 and 
TNF were elevated in Huntington’s disease patient (A) blood monocytes and (B) 
macrophages collected from two independent patient cohorts, stimulated in vitro with 10 ng/ml 
IFN and 2 g/ml LPS for 24 h. Data show mean concentrations +/- SEM, n= individual 
biological repeats, ANOVA with post-hoc Tukey HSD test. *p>0.05; **p>0.01, ***p>0.001. 
 
Figure 2: Glucan encapsulated siRNA particles (GeRPs) can effectively knock-down total 
HTT in primary human immune cells. (A) GeRPs deliver siRNA efficiently when 
phagocytosed by myeloid cells, as shown in primary human monocytes after 12 h incubation 
in culture (GeRPs = green; DAPI = blue). (B) 90% of macrophages take up GeRPs when 
incubated at 1:10 cell: particle ratio for 12 h as quantified by flow cytometry. Data shown as 
mean (n=2 for controls and n=3 for Huntington’s disease) +/- SEM. (C) Total HTT RNA 
measured by qPCR and protein levels measured by TR-FRET were reduced by 70 and 50%, 
respectively, in macrophages treated for 3 days with GeRPs containing anti-HTT siRNA. Data 
shown as mean HTT levels (each combining two independent experiments, n stands for 
individual biological repeats) +/- SEM. Data is normalised to the scrambled siRNA treated 
condition for each genotype. 
 
Figure 3: Knock-down of total HTT reverses the hyper-reactive cytokine production by 
Huntington’s disease macrophages. Huntington’s disease and control macrophages were 
treated with either anti-HTT or scrambled siRNA for 3 days, before the cells were stimulated 
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with 10 ng/ml IFN and 2 g/ml LPS for 24 h. Measuring cytokine production with multiplex 
ELISA assays showed that lowering HTT levels reduces IL-6, IL-8 and TNF levels following 
stimulation. Data shown as mean concentrations (n=9 for controls and n=8 for Huntington’s 
disease, combined from 3 independent experiments, n stands for individual biological repeats) 
+/- SEM, two-way ANOVA with Bonferroni post-tests. *p>0.05; **p>0.01, ***p>0.001. 
 
Figure 4: Expression of mutant HTT induces elevated cytokine production. U937 cells 
were lentivirally-transduced with (m)HTT exon 1 containing either 29, 71 or 129 glutamine 
(Q) repeats or an empty vector. (A) Expression of (m)HTT protein post-transduction was 
confirmed, with increased levels of soluble HTT in all three cell lines expressing exogenous 
HTT. (B) Innate immune regulators were elevated in PMA-differentiated mutant HTT 
expressing U937 cells stimulated for 24 h with 10 ng/ml IFN and 2 g/ml LPS. Data shown 
as mean concentrations (n=3 technical repeats for all conditions) +/- SEM, two-way ANOVA 
with Bonferroni post-tests, *p>0.05; **p>0.01, ***p>0.001. Experiment was repeated three 
times independently showing similar results. 
 
Figure 5: HTT interacts directly with the NFB pathway, which is dysregulated in 
Huntington’s disease. (A) HTT interacts directly with IKK, as shown by PLA. Monocyte-
derived macrophages were differentiated on glass cover slips and stained for HTT and IKKor 
IKK before antibodies binding in close proximity were visualised using PLA-probes as red 
spots, shown here. Cells stained with a single primary antibody did not result in red spots. (B) 
Quantification of the number of spots per cell using the Volocity software shows increased 
binding between  and HTT in Huntington’s disease compared to control cells (p=0.06). 
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Binding of HTT to the  and  subunit of IKK showed a similar, but smaller trend (p=0.1). 
Two-tailed unpaired t test used for statistical analysis. (C) While in control cells LPS-induced 
degradation of IB occurred within 15 min of stimulation with LPS and recovered within 2 h, 
Huntington’s disease monocytes demonstrate a more rapid loss of IκB and no recovery of the 
protein. Shown is an example blot of samples from one control and one Huntington’s disease 
subject. (D) Translocation of the NFB transcription factor RelA to the nucleus after LPS 
stimulation was measured using imaging flow cytometry; example images are shown here. In 
untranslocated cells the green RelA staining surrounds the nuclear DAPI staining, while in cells 
demonstrating translocation of RelA the colours merge. (E) Increased RelA translocation into 
the nucleus following LPS stimulation was observed in Huntington’s disease monocytes (n=7) 
compared to controls (n=8). n= individual biological repeats. Data shown as mean 
concentrations +/- SEM, two-way ANOVA with Bonferroni post-tests, *p>0.05; **p>0.01. All 
experiments were repeated at least twice with the same results. 
 
Figure 6: Lowering total HTT levels reverses transcriptional changes found in 
Huntington’s disease monocytes. Huntington’s disease and control monocytes were 
incubated with either scrambled or anti-HTT siRNA containing GeRPs for 3 days before RNA 
isolation. Using qPCR, efficient HTT knock-down was demonstrated as well, as lowering of 
key NFB pathway molecules IRAK1, CD40 and JUN in (A) Huntington’s disease patient cells 
but not (B) controls. Data shown as relative gene expression (n= 10 individual biological 
repeats for controls and Huntington’s disease) +/- SEM, paired t test *p>0.05; **p>0.01. 
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Figure 7: Mechanism of immune dysfunction in Huntington’s disease. (A) In normal wild-
type HTT expressing myeloid cells, LPS binds the TLR4 receptor activating the NFB pathway 
triggering production of pro-inflammatory cytokines such as IL-6 and TNFα. (B) Mutant HTT 
interferes with the NFB pathway by two distinct mechanisms. The mutant protein binds IKK 
to directly cause increased IB degradation and NFB transcription factor translocation, 
allowing increased transcription of target genes such as IL-6 and TNF. Moreover, mutant 
HTT causes transcriptional changes leading to increased expression of key molecules within 
the signalling cascade likely to increase signalling transduction rate. 
 
Table 1: The top twenty gene changes within the NFB pathway observed in 
Huntington’s disease monocytes. Data presented as fold change calculated from delta-delta-
CT values, unpaired two-tailed t test used as statistical method. 
 
 
 
